SS Innovations International (NASDAQ: SSII) has announced the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo, utilizing the company's SSi Mantra 3.0 surgical robotic system. This development not only marks a milestone for Sri Lanka's healthcare sector but also underscores the expanding global footprint of robotic-assisted surgery and SS Innovations' role in driving that adoption.
The program's inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. The successful launch demonstrates the feasibility and potential of robotic systems in complex cardiac procedures, which traditionally require open-heart surgery with lengthy recovery times. By bringing this technology to Sri Lanka, SS Innovations is helping to elevate the standard of care in the region and potentially reduce the need for patients to travel abroad for advanced surgical interventions.
According to a recent company video describing the program's early activity, Kings Hospital has completed more than 25 robotic procedures in just three weeks. This rapid adoption rate suggests strong local demand and a willingness among surgeons to integrate robotic assistance into their practice. The quick uptake also highlights the SSi Mantra's versatility and ease of use, as it is being employed across a range of procedures, not just cardiac surgery.
SS Innovations reported 224 cumulative SSi Mantra installations across 12 countries at the end of the second quarter. This figure reflects the company's growing international presence and the increasing acceptance of its robotic platform in diverse healthcare markets. The company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. These numbers point to rising utilization of the company's installed base, a key metric that indicates surgeons are not only adopting the technology but also using it regularly, which is essential for long-term revenue growth and clinical validation.
The next major corporate milestone for SS Innovations is regulatory expansion, with the company pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up the world's largest healthcare markets, significantly broadening the company's addressable market and potentially accelerating revenue growth. It would also provide further validation of the system's safety and efficacy, which could drive adoption in other countries as well.
For investors, the Sri Lanka launch and the company's strong procedure growth signal that SS Innovations is executing on its strategy to penetrate new geographies and expand its installed base. The pursuit of FDA clearance and CE marking represents a critical catalyst that could transform the company's competitive position. As robotic surgery continues to gain traction globally, SS Innovations' progress in these areas will be closely watched. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. For full terms of use and disclaimers, please see the InvestorBrandNetwork website at https://IBN.ai/Disclaimer.
